PTCH1 and neoplasm: This is in the range of the risk described in PTCH1-associated GS, where tumour risk has been estimated around 55%–60%.19 In addition, we could confirm that the spectrum of SUFU-associated GS differs from PTCH1-associated GS as previously suggested in smaller studies.19 31